Hauck & Aufhaeuser set a €120.00 ($141.18) target price on Carl Zeiss Meditec (ETR:AFX) in a report issued on Friday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
Several other analysts have also commented on the stock. Nord/LB set a €110.00 ($129.41) target price on shares of Carl Zeiss Meditec and gave the company a buy rating in a research note on Monday, August 10th. UBS Group set a €105.00 ($123.53) price objective on Carl Zeiss Meditec and gave the stock a buy rating in a research note on Monday, August 10th. Berenberg Bank set a €87.00 ($102.35) target price on Carl Zeiss Meditec and gave the stock a neutral rating in a research report on Thursday, July 16th. Independent Research set a €76.00 ($89.41) target price on Carl Zeiss Meditec and gave the company a sell rating in a report on Wednesday, August 19th. Finally, Deutsche Bank set a €110.00 ($129.41) price target on Carl Zeiss Meditec and gave the stock a buy rating in a research note on Thursday, August 6th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Carl Zeiss Meditec presently has an average rating of Hold and a consensus price target of €99.63 ($117.21).
Shares of ETR:AFX opened at €101.40 ($119.29) on Friday. Carl Zeiss Meditec has a 12 month low of €67.70 ($79.65) and a 12 month high of €122.10 ($143.65). The company has a debt-to-equity ratio of 3.62, a current ratio of 4.06 and a quick ratio of 3.05. The business has a 50-day moving average of €92.86 and a two-hundred day moving average of €90.76. The firm has a market capitalization of $9.07 billion and a PE ratio of 75.96.
About Carl Zeiss Meditec
Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.
Recommended Story: Cash Asset Ratio
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.